Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma

Alberto Papi, Irene Braithwaite, Stefan Ebmeier, Robert J. Hancox, Tim Harrison, Mark Holliday, Claire Houghton, Luca Morandi, Karen Oldfield, Ian D. Pavord, Helen K. Reddel, Mathew Williams, Mark Weatherall, Richard Beasley

Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020
Journal Issue: February
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Alberto Papi, Irene Braithwaite, Stefan Ebmeier, Robert J. Hancox, Tim Harrison, Mark Holliday, Claire Houghton, Luca Morandi, Karen Oldfield, Ian D. Pavord, Helen K. Reddel, Mathew Williams, Mark Weatherall, Richard Beasley. Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma. Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Formoterol Turbuhaler as reliever medication in patients with acute asthma
Source: Eur Respir J 2006; 27: 735-741
Year: 2006



Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003

Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 43s
Year: 2001

Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 52s
Year: 2002

Effect of budesonide/formoterol, budesonide and terbutaline on exercise-induced bronchoconstriction in mild intermittent asthma
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Intermittent therapy with budesonide/formoterol in children with moderate asthma.
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017


Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018




Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007


Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid
Source: Eur Respir J 2002; 20: Suppl. 38, 113s
Year: 2002